Back
“A pure-play clinical-trial CRO climbs as AI multiplies drug candidates and the work of running and approving trials becomes the real chokepoint, with the stock already beaten down on the opposite fear.”
Source
Dwarkesh PodcastYouTube“Dario Amodei — “We are near the end of the expon…”102:28
“I actually worry more about the drug approval process where I think AI models are going to greatly accelerate the rate at which we discover drugs and just the pipeline will get jammed up, like the pipeline will not be prepared to, like, process all of the stuff that's going through it.”
Performance
Entry$428.03
Current—
Since call— pending
Confidence72%
How this was scored
Entry$428.03Feb 13, 2026 · 17:11 UTC · paste.trade
Horizonnot specifiedparsed as default-30d
Verdict bandWIN ≥ +2% · LOSS ≤ −2%
Prices are point-in-time snapshots from the named provider. The verdict compares the return since entry against the band above.